GM237354: a sordarin derivative [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 177413 |
| MeSH ID | M0368759 |
| Synonym |
|---|
| gm237354 |
| 199013-04-2 |
| ((1r-(1alpha,3abeta,4alpha,4abeta,7beta,7aalpha, 8abeta))-8a-((1s,2r,4r,6r)-cis-2-methyl-7-methylene-3,9-dioxabicyclo(4.3.0)nonan-4-yloxy-methyl)-3-isopropyl-4-formyl-7-methyl-1,3a,4,4a,5,6,7,7a,8,8a-decahydro-1,4-methano-s-indacene-3a-carboxylic acid |
| (1r,2s,4r,5r,8r,9s,11s)-2-[[(3ar,5r,7r,7as)-7-methyl-3-methylidene-4,5,7,7a-tetrahydro-3ah-furo[2,3-c]pyran-5-yl]oxymethyl]-9-formyl-5-methyl-13-propan-2-yltetracyclo[7.4.0.02,11.04,8]tridec-12-ene-1-carboxylic acid |
GM237354 is a novel sordarin derivative with a broad spectrum of potent activity against a wide range of fungi.
| Excerpt | Reference | Relevance |
|---|---|---|
| "GM237354 is a novel sordarin derivative with a broad spectrum of potent activity against a wide range of fungi. " | ( Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats. Gargallo-Viola, D; Jimenez, E; Martinez, A; Regadera, J; Santos, I, 2001) | 2.06 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The present study investigates possible correlations between sordarin pharmacokinetic (PK) properties and therapeutic efficacy, based on a murine model of invasive systemic candidiasis, and provides a rationale for dose selection in the first study of efficacy in humans." | ( Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis. Aviles, P; Falcoz, C; Gargallo-Viola, D; San Roman, R, 2000) | 0.31 |
| "The antifungal effect of GM 237354, a sordarin derivative, was studied in an in vitro pharmacokinetic (PK)-pharmacodynamic dynamic system (bioreactor) which reproduces PK profiles observed in a previously described model of drug efficacy against murine systemic candidiasis." | ( Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding. Aviles, P; Falcoz, C; Gargallo-Viola, D; Gómez De Las Heras, F; Guillén, MJ; San Roman, R, 2001) | 0.31 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " A good correlation independent of the dosing interval was observed with AUC (but not C(max) or t > MIC) and both AUSTC and kidney burden." | ( Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis. Aviles, P; Falcoz, C; Gargallo-Viola, D; San Roman, R, 2000) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||